Problems and Solutions in Chinese Pharmaceutical Industry

Authors

  • Xueyi Zhu

DOI:

https://doi.org/10.62051/kebcd272

Keywords:

Chinese pharmaceutical industry; Generic drugs; Innovation ability; Medical insurance payment; Supply chain.

Abstract

The Chinese pharmaceutical industry plays an important role in the Chinese society. With the aging of the population and the improvement of residents' health awareness, it has become a key area to ensure public health and improve the quality of life. In addition, it also contributes to the steady development of Chinese economy, increasing a lot of employment opportunities and promoting scientific and technological innovation. Through the improvement of self-sufficiency in China's pharmaceutical industry, the industry has not reduced its foreign dependence, but increased China's international influence as well. However, it also brings about a series of problems. This study will explain the problems in the pharmaceutical industry from four perspectives of generic drugs, innovation ability, medical insurance payment and supply chain. This paper will review the past and current situation of Chinese pharmaceutical industry through the problems and express the future expectations for the industry. According to these expectations, the relative countermeasures and suggestions will be put forward. This study is of great significance for the healthy development of the Chinese pharmaceutical industry.

Downloads

Download data is not yet available.

References

[1] A. Kumar, et al. When Risks Need Attention: Adoption of Green Supply Chain Initiatives in the Pharmaceutical Industry. International journal of production research. 57 (2019) 3554–3576.

[2] E. Barbieri. Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions. International journal of environmental research and public health. 14 (2017) 1179.

[3] L. H. Kong, et al. Innovation in the Chinese Pharmaceutical Industry. Nature Reviews Drug discovery. 22 (2023) 12–13.

[4] J. H. He, et al. Physicians’ Perceptions of Generic Drugs in China. Health Policy OPEN. 3 (2022) 100067.

[5] J. Ni, J. Zhao, C. O. L. Ung, et al. Obstacles and opportunities in Chinese pharmaceutical innovation. Global Health. 13 (2017).

[6] R. Y. Wang, Y. D. Zhou. Can R&D Input Influence Market Power? Facts about China’s Pharmaceutical Manufacturing Industry. Journal of institutional and theoretical economics. 177 (2021) 428–448.

[7] Y. Liang, L. Hong, N. Kirsten Corazzini. Predictors and Patterns of Home Health Care Utilization among Older Adults in Shanghai, China. Home health care services quarterly. 38 (2019) 29–42.

[8] Mulcahy, W. Andrew, K. Vishnupriya. Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships. Rand health quarterly. 9 (2022) 7

[9] L. M. Liang. Design of the Internet plus Drug Circulation Business Model Based on Value Chain. Journal of healthcare engineering. (2021) 6673649.

[10] Z. B. Cui, et al. Blockchain Adoption for Generic Drugs in the Medicine Supply Chain with Consumers’ Risk-Aversion: A Game-Theoretic Model within Chinese Legal Framework. Risk management and healthcare policy. 17 (2024) 15–28.

Downloads

Published

23-12-2024

How to Cite

Zhu, X. (2024). Problems and Solutions in Chinese Pharmaceutical Industry. Transactions on Economics, Business and Management Research, 14, 66-71. https://doi.org/10.62051/kebcd272